Table 1. Criteria of the drugs classified by degree of immunosuppression.

Degree	Large category	Category	Examples of the drugs
Mild	Steroids	Steroids	Equivalent to prednisolone < PSL 20 mg/d or < 2 weeks
	Immune checkpoint inhibitors	CTLA-4 inhibitors	Ipilimumab
		PD-1 inhibitors	Nivolumab, pembrolizumab
		PD-L1 inhibitors	Avelumab, atezolizumab, durvalumab
	Tyrosine kinase inhibitors	ALK inhibitors	Crizotinib, ceritinib, alectinib, brigatinib
		BCR-Abl inhibitors	Imatinib, nilotinib, dasatinib, bosutinib
		EGFR inhibitors	Cetuximab, panitumumab, vandetanib, lapatinib, gefitinib, erlotinib, lenvatinib, afatinib, osimertinib
		HER2 inhibitors	Trastuzumab, pertuzumab
		PDGFR α/β inhibitors	Gefitinib, imatinib, lenvatinib, nintedanib, pazopanib, regorafenib, sorafenib, sunitinib
		VEGFR inhibitors	Ramucirumab, bevacizumab, lenvatinib, nintedanib, regorafenib, pazopanib, sorafenib, sunitinib
	Serine/threonine kinase	BRAF inhibitors	Vemurafenib, dabrafenib
	inhibitors
		CDK 4/6 inhibitors	Palbociclib, sorafenib, ribociclib
	Hormonal therapies	Hormonal therapies	Tamoxifen
	Cytotoxic drugs	DNA synthesis inhibitors	Methotrexate(< 20 mg/week)
		Folic acid synthesis inhibitors	Azathioprine(< 3 mg/kg/day), mercaptopurine(< 1.5 mg/kg/day),
	Interleukin inhibitors	IL-4/13 inhibitors	Dupilumab
		IL-12/23 inhibitors	Ustekinumab
		IL-17 inhibitors	Ixekizumab, secukinumab
	DMARDs	DMARDs	Hydroxychloroquine, salazosulfapyridine, igratimod, bucillamine, leflunomid
	Gut-specific integrins	Anti-α4β7integrin	Vedolizumab, natalizumab
	Others	Drugs associated with multiple sclerosis	Dimetyl fumarate, fingolimod, glateramer acetate, interferon-β 1a
Moderate	Steroids	Steroids	Equivalent to prednisolone ≥ PSL 20 mg/d and ≥ 2 weeks
	DMARDs	DNA synthesis inhibitors	Mercaptopurine(≥ 1.5 mg/kg/day), azathioprine(≥ 3 mg/kg/day), mycophenolate mofetil, mizoribine
	Cytotoxic drugs	Alkylating drugs	Temozolomide, ranimustine, melphalan, ifosphamide, cyclophosphamide
		Antibiotics	Doxorubicin, epirubicin, idarubicin, aclarubicin, amrubicin, daunorubicin, bleomycin, mitomycin C, actinomycin D,
		Antimetabolites	Fluorouracil/tegafur, gemcitabine, capecitabine, cytarabine
		Calcineurin inhibitors	Tacrolimus, cyclosporin A
		Folic acid synthesis inhibitors	Methotrexate(≥ 20 mg/week)
		Microtubule inhibitors	Paclitaxel, docetaxel
		Platinum-based drugs	Cisplatin, carboplatin, nedaplatin
		Proteasome inhibitors	Bortezomib
		Topoisomerase inhibitors	Irinotecan, nogitecan
	Immunomodulators	CTLA-4	Abatacept
		IL-2 inhibitors	Basiliximab
		IL-6 inhibitors	Tocilizumab, sarilumab
	Tyrosine kinase inhibitors	JAK inhibitors	Baricitinib, peficitinib, tofacitinib, ruxolitinib
	Molecular-targeted drugs	mTOR inhibitors	Everolimus, sirolimus, rapalimus
		TNF-α inhibitors	Etanercept, certolizumab, golimumab, adalimumab, infliximab
Severe	B-cell depleting therapies	Anti-CD19 inhibitors	Inebilizumab
		Anti-CD20 inhibitors	Rituximab, obinutuzumab, ofatumumab
		Anti-CD38 inhibitors	Daratumumab
		Anti-CD52 inhibitors	Alemtuzumab
	Tyrosine kinase inhibitors	Bruton kinase inhibitors	Iburutinib, acalabrutinib, tirabrutinib